Phase 2
Completed N=14
Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients
Epidermolysis Bullosa · Pruritus
Source: ClinicalTrials.gov NCT02654483 ↗
Enrolled (actual)
14
Serious AEs
9.1%
Results posted
Jul 2019
Primary outcomePrimary: Comparative Weekly Change in NRS Itch Score Over the 8-week Active Treatment Period — -2; -1 score/week comparative change
Summary
Our goal is to determine whether daily oral administration of VPD-737 (5 mg) is effective and safe in treating moderate to severe pruritus in patients with Epidermolysis Bullosa (EB).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Comparative Weekly Change in NRS Itch Score Over the 8-week Active Treatment Period |
-2; -1 | — |
| SECONDARY Wound Healing Determination |
154.54; 38.39 | — |
| SECONDARY Change in Mean NRS Itch Score During Bathing/Dressing Changes |
-2.5; -2 | — |
Eligibility Criteria
Inclusion Criteria
- Clinical diagnosis of Epidermolysis Bullosa (EB) and pruritus
Exclusion Criteria
- Chronic liver or renal disease
Data sourced from ClinicalTrials.gov (NCT02654483). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.